Vontobel Holding Ltd. Has $4.66 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vontobel Holding Ltd. increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,339 shares of the biopharmaceutical company's stock after acquiring an additional 881 shares during the quarter. Vontobel Holding Ltd.'s holdings in Regeneron Pharmaceuticals were worth $4,655,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Capital International Investors raised its stake in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after buying an additional 1,390,534 shares during the last quarter. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $802,036,000. GAMMA Investing LLC lifted its stake in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the period. Finally, Amundi raised its position in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after purchasing an additional 487,489 shares during the period. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

REGN has been the topic of a number of research analyst reports. UBS Group reduced their price target on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, Citigroup decreased their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research report on Monday, June 2nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $822.58.

Regeneron Pharmaceuticals Price Performance

REGN opened at $545.00 on Friday. The firm has a market cap of $58.84 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 2.01 and a beta of 0.33. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a fifty day simple moving average of $550.54 and a 200 day simple moving average of $627.29.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $9.55 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.